Table 3. Regression Analysis Results and Sample Mean Market Shares, 2006-2012.

	No. of Observationsa	Detailed Drugs			Nondetailed Drugs
		Mean Market Share, 2006-2012, %b	Change in Market Share After Implementation of Detailing Policy, Percentage Points (95% CI)c	P Value	Mean Market Share, 2006-2012, %b	Change in Market Share After Implementation of Detailing Policy, Percentage Points (95% CI)c	P Value
All Academic Medical Centers (AMCs) and All Drugs	14 791 612	19.3	−1.67 (−2.18 to −1.18)	<.001	14.2	0.84 (0.54 to 1.14)	<.001
AMC-Specific Results Ordered by Date of Policy Intervention
Stanford University School of Medicine	122 319	21.7	−1.05 (−2.91 to 0.80)	.27	15.1	−0.23 (−1.46 to 1.01)	.72
Northwestern University Feinberg School of Medicine	385 205	23.1	−0.65 (−3.40 to 2.11)	.64	15.4	−0.06 (−1.71 to 1.68)	.94
University of California-Davis School of Medicine	120 327	19.1	−2.13 (−5.19 to 0.96)	.18	14.0	1.37 (−0.49 to 3.23)	.15
University of California-Los Angeles School of Medicine	2 539 672	18.3	−2.72 (−4.39 to −1.04)	.02	13.4	1.60 (0.80 to 2.40)	<.001
University of California-San Francisco School of Medicine	232 137	21.9	0.54 (−1.54 to 2.67)	.62	16.3	0.21 (−0.21 to 0.64)	.33
Boston University School of Medicine	610 277	14.8	−2.48 (−4.93 to −0.04)	.05	14.9	1.92 (−0.63 to 4.47)	.14
University of Illinois-Chicago College of Medicine	501 076	21.0	−2.03 (−3.70 to −0.38)	.02	13.9	1.56 (0.15 to 2.96)	.03
Mount Sinai School of Medicine	605 651	21.2	−2.29 (−5.09 to 0.51)	.11	12.6	−0.14 (−3.23 to 2.97)	.93
University of Southern California Keck School of Medicine	869 500	19.4	−1.87 (−3.69 to −0.02)	.04	13.7	0.90 (−0.21 to 2.00)	.11
University of Pittsburgh School of Medicine	1 058 972	19.9	−1.96 (−2.87 to −0.82)	<.001	13.8	1.23 (0.52 to 1.95)	<.001
University of Rochester School of Medicine	116 538	21.9	−1.46 (−5.30 to 2.61)	.48	18.6	1.03 (−1.82 to 3.87)	.48
University of California-San Diego School of Medicine	1 180 198	19.2	−0.62 (−1.23 to −0.02)	.03	14.2	0.40 (0.01 to 0.62)	.03
University of Massachusetts Medical School	769 198	15.8	−1.51 (−2.17 to −0.85)	<.001	13.8	1.47 (0.79 to 2.15)	<.001
Rush Medical College	4 246 339	17.7	−0.91 (−2.23 to 0.41)	.18	11.8	0.62 (0.01 to 1.22)	.04
Temple University School of Medicine	233 190	22.3	0.32 (−7.29 to 7.34)	.94	16.7	−0.51 (−12.88 to 11.89)	.93
New York Medical College	300 923	22.5	−4.72 (−11.27 to 1.80)	.16	15.4	0.37 (−1.80 to 2.56)	.74
State University of New York, Downstate Medical School	325 786	21.9	−1.59 (−2.87 to −0.31)	.01	14.0	1.58 (0.84 to 2.31)	<.001
Tufts University School of Medicine	434 177	17.6	−1.02 (−2.02 to −0.01)	.04	17.6	0.70 (0.02 to 1.36)	.04
Thomas Jefferson University Medical College	140 109	21.5	−1.23 (−4.36 to 1.89)	.44	14.6	0.51 (−0.37 to 1.40)	.25
Drug Class–Specific Results Ordered by Size of Effect
Sleep aidsd	375 753	51.4	−10.5 (−18.87 to −2.16)	.01	50.9	4.67 (0.81 to 8.50)	.02
Gastroesophageal reflux disease drugs	1 166 894	37.0	−6.89 (−9.10 to −4.70)	<.001	22.7	3.98 (2.63 to 5.31)	<.001
Attention-deficit/hyperactivity disorder drugs	149 703	29.0	−5.03 (−9.92 to −0.05)	.04	40.6	2.51 (−1.02 to 6.05)	.16
Antidepressant drugs	2 453 111	22.5	−2.32 (−3.26 to −1.37)	<.001	12.4	1.17 (0.68 to 1.66)	<.001
Lipid-lowering drugs	2 490 775	28.8	−1.51 (−2.36 to −0.66)	.001	10.5	1.31 (0.69 to 1.92)	<.001
Antihypertensive drugs	5 496 003	9.2	−0.84 (−1.34 to −0.35)	.002	9.1	0.67 (0.37 to 0.96)	<.001
Antipsychotic drugs	335 149	37.8	−0.55 (−2.79 to 1.70)	.63	28.0	0.89 (−0.53 to 2.32)	.22
Diabetes drugs	2 311 089	10.9	0.60 (−0.26 to 1.47)	.24	16.6	−0.05 (−1.08 to 0.98)	.92

^aTotal number of physician-drug-month observations for the given sample.

^bGiven as a reference to interpret the size of the reported change in market share associated with AMC policies restricting pharmaceutical detailing.

^cAssociated with AMC policies restricting pharmaceutical detailing.

^dHypnotic drugs approved for the treatment of insomnia.